Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma

Tsung Chieh Shih, Lijun Wang, Hsiao Chi Wang, Yu Jui Yvonne Wan

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a great need to develop efficacious treatment against this debilitating disease. Glypican-3 (GPC3), a member of the glypican family that attaches to the cell surface by a glycosylphosphatidylinositol anchor, is overexpressed in HCC cases and is elevated in the serum of a large proportion of patients with HCC. GPC3 expression contributes to HCC growth and metastasis. Furthermore, several different types of antibodies targeting GPC3 have been developed. The aim of this review is to summarize the current literatures on the GPC3 expression in human HCC, molecular mechanisms of GPC3 regulation and antibodies targeting GPC3.

Original languageEnglish (US)
Pages (from-to)168-172
Number of pages5
JournalLiver Research
Issue number4
StatePublished - Dec 2020


  • Glypican-3 (GPC3)
  • Hepatocellular carcinoma (HCC)
  • Wnt signaling

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this